<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00621920</url>
  </required_header>
  <id_info>
    <org_study_id>PL07.01</org_study_id>
    <nct_id>NCT00621920</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Bowel Preparation Before Colonoscopy</brief_title>
  <official_title>Efficacy Study of Bowel Preparation Before Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C.B. Fleet Company, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C.B. Fleet Company, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacious dose range when used as a bowel&#xD;
      preparation before colonoscopy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of bowel cleansing based on a grading scale.</measure>
    <time_frame>During colonoscopy</time_frame>
  </primary_outcome>
  <enrollment type="Actual">72</enrollment>
  <condition>Bowel Cleansing Prior to Colonoscopy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FM-601</intervention_name>
    <description>Dose-escalation, split dosage, liquid</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and nonpregnant women who are scheduled for an elective colonoscopy and who are at&#xD;
             least 50 years of age.&#xD;
&#xD;
          -  Are able to communicate with study personnel and comply with study requirements.&#xD;
&#xD;
          -  Are able and willing to follow study-specified testing, diet, and hydration regimen.&#xD;
&#xD;
          -  Have been informed of the nature and risks of the study and have given written&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have known or suspected liver disease or any history of abnormal liver function tests.&#xD;
&#xD;
          -  Have clinically active cardiovascular disease within the past 6 months.&#xD;
&#xD;
          -  Have blood pressure greater than 150/90 mm Hg.&#xD;
&#xD;
          -  Have known or suspected renal insufficiency.&#xD;
&#xD;
          -  Have known or suspected electrolyte abnormalities, gastrointestinal obstruction,&#xD;
             gastric retention, bowel perforation, toxic colitis, toxic megacolon, or ileus.&#xD;
&#xD;
          -  Have a history of prior bowel surgery within 2 years before enrollment, or active&#xD;
             inflammatory bowel disease.&#xD;
&#xD;
          -  Have diabetes or a history of diabetes.&#xD;
&#xD;
          -  Have clinical evidence of dehydration.&#xD;
&#xD;
          -  Are pregnant or breast-feeding.&#xD;
&#xD;
          -  Are unwilling to abstain from alcohol consumption from one day before colonoscopy&#xD;
             until discharged from the study.&#xD;
&#xD;
          -  Use prohibited medications of the study in the defined timeframes.&#xD;
&#xD;
          -  Have received any investigational agent within 30 days before dosing.&#xD;
&#xD;
          -  Have any known contraindications to the study treatment.&#xD;
&#xD;
          -  Have any known or suspected allergies to the components of the study medication.&#xD;
&#xD;
          -  Have any other condition which would make the subject unsuitable for inclusion in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qualia Clinical Services</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>February 12, 2008</study_first_submitted>
  <study_first_submitted_qc>February 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <last_update_submitted>February 8, 2012</last_update_submitted>
  <last_update_submitted_qc>February 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

